Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ALPG | P10696 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | CASP6 | P55212 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 8/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862889 | 0.87 | NPC1 (0.76) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL7939950 | 0.85 | NPC1 (0.81) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL10964996 | 0.85 | NPC1 (0.73) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL653535 | 0.82 | GSK3B (0.68) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL9712507 | 0.82 | GSK3B (0.68) | NPC1RAB9AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL124008 | 0.81 | NPC1 (0.91) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL2968369 | 0.81 | GSK3B (0.67) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL8733595 | 0.81 | NPC1 (1.00) | NPC1RAB9AKDM4EALDH1A1ABL1 | |
| SCHEMBL2337097 | 0.80 | KMT2A (0.64) | NPC1RAB9AALDH1A1POLBL3MBTL1 | |
| SCHEMBL117311 | 0.80 | NPC1 (0.69) | NPC1RAB9AALDH1A1L3MBTL1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-116283619-A | Salbutamol sulfate impurity and preparation method thereof | 河北广祥制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| WO-2021062048-A2 | METHODS AND SYSTEMS FOR MODULATING HEPATIC GABA PRODUCTION OR RELEASE TO ALTER FOOD INTAKE IN MONOGASTRIC SPECIES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-04-01 | — | — | WO | claimed |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| CN-117721474-A | Cleaning agent for chip after chemical mechanical polishing, preparation method and application thereof | 江苏奥首材料科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-116283619-A | Salbutamol sulfate impurity and preparation method thereof | 河北广祥制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116283619-A | Salbutamol sulfate impurity and preparation method thereof | 河北广祥制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230128194-A1 | METHODS AND COMPOSITIONS TO ALTER HEPATIC GABA RELEASE TO TREAT OBESITY-RELATED CONDITIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-04-27 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| EP-0038071-B1 | NEW UNLABELLED AND RADIOACTIVE LABELLED DERIVATIVES OF BUTYLAMINO PROPIOPHENONE, THEIR PREPARATION, IMMUNOGENS OBTAINED FROM THE UNLABELLED DERIVATIVES AND A PROCESS FOR IMMUNOGEN PREPARATION, ANTISERA RAISED USING THE IMMUNOGENS AND A METHOD FOR RAISING ANTISERA, A RADIOIMMUNOASSAY METHOD AND A TEST KIT FOR USE IN THE ASSAY METHOD | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-11-14 | — | — | EP | disclosed |
| US-4356165-A | Bupropion radioimmunoassay, and kit | BURROUGHS WELLCOME CO. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4355179-A | Radioactive nuclide labeled propiophenone compounds | BURROUGHS WELLCOME CO. (US) | 1982-10-19 | — | — | US | disclosed |
| US-4347177-A | Compounds and methods of making them | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347382-A | 3H Labeled compounds | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347178-A | Compounds and methods of making | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4347176-A | Compounds and methods of making same | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
| EP-0038071-A2 | New unlabelled and radioactive labelled derivatives of butylamino propiophenone, their preparation, immunogens obtained from the unlabelled derivatives and a process for immunogen preparation, antisera raised using the immunogens and a method for raising antisera, a radioimmunoassay method and a test kit for use in the assay method | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | NPC1 710/4885RAB9A 3086/4885KDM4E 1904/4885 |
| US-12161624-B2 | Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B | GRIN2A, GRIN2C, GRIN3A | NPC1 710/4885RAB9A 3086/4885KDM4E 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.